OncoMatch/Clinical Trials/NCT06403111
FMT+Immunotherapy+Chemotherapy As First-line Treatment for Driver-gene Negative Advanced NSCLC
Is NCT06403111 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Fecal Microbiota Transplantation (FMT)+chemotherapy+immunotherapy for non-small cell lung cancer.
Treatment: Fecal Microbiota Transplantation (FMT)+chemotherapy+immunotherapy — This study plans to reconstruct intestinal microecology through fecal microbiota transplantation (FMT), and combine with standard first-line therapy to enhance the anti-tumor immune effect at the same time, thereby extending the progression-free survival of patients and improving the prognosis of patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR wild-type
the driver gene is negative
Required: ALK wild-type
the driver gene is negative
Required: ROS1 wild-type
the driver gene is negative
Required: BRAF wild-type
the driver gene is negative
Required: MET wild-type
the driver gene is negative
Required: RET wild-type
the driver gene is negative
Required: HER2 (ERBB2) wild-type
the driver gene is negative
Required: KRAS wild-type
the driver gene is negative
Required: PD-L1 (CD274) expression < 50% (< 50%)
PD-L1 expression < 50%
Disease stage
Required: Stage IIIB, IIIC, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: systemic intravenous anti-tumor therapy
Have not received systemic intravenous anti-tumor therapy before
Lab requirements
Blood counts
ANC ≥1.5×10^9/L; PLT ≥75×10^9/L; HGB ≥90 g/L (no blood transfusion or erythropoietin dependence within 14 days)
Kidney function
serum creatinine ≤1.5x ULN or creatinine clearance ≥50 mL/min; urine protein <2+; if ≥2+, 24-hour urine protein <1g
Liver function
serum total bilirubin (TBIL) ≤2x ULN; ALT and/or AST ≤5x ULN; serum albumin ≥28 g/L; ALP ≤5x ULN
adequate organ and bone marrow function, laboratory examination within 7 days prior to enrollment meets the following requirements...
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06403111 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require EGFR?
Yes, EGFR wild-type is a required biomarker for enrollment.
Does this trial require ALK?
Yes, ALK wild-type is a required biomarker for enrollment.
Does this trial require ROS1?
Yes, ROS1 wild-type is a required biomarker for enrollment.
What disease stage is eligible?
Stage IIIB or IIIC or IV is required.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify